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Summary
Multi-Arm Multi-Stage (MAMS) platform trials are an efficient tool for the comparison of sev-
eral treatments with a control. Suppose a new treatment becomes available at some stage of a
trial already in progress. There are clear benefits to adding the treatment to the current trial for
comparison, but how?
As flexible as the MAMS framework is, it requires pre-planned options for how the trial pro-
ceeds at each stage in order to control the familywise error rate. Thus, as with many adaptive
designs, it is difficult to make unplanned design modifications. The conditional error approach is
a tool that allows unplanned design modifications while maintaining the overall error rate. In this
work we use the conditional error approach to allow adding new arms to a MAMS trial in progress.
Using a single stage two-arm trial, we demonstrate the principals of incorporating additional
hypotheses into the testing structure. With this framework for adding treatments and hypotheses
in place, we show how to update the testing procedure for a MAMS trial in progress to incorporate
additional treatment arms. Through simulation, we illustrate the operating characteristics of such
procedures.
Key words: multi-arm multi-stage (MAMS), adaptive designs, conditional error, design modification
1. Introduction
During Phase II of the drug development process it is common to have several competing treat-
ments, these may simply be different doses of the same drug or entirely different treatment
regimes. Jaki and Hampson (2016) note that, given the high failure rate and cost of Phase III
∗To whom correspondence should be addressed.
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trials, it is key to that careful consideration be given to which treatments should be carried for-
ward for further study. Multi-arm multi-stage trials (MAMS) (Royston and others, 2003; Jaki,
2013) allow for the efficient comparison of several experimental treatments with a common con-
trol allowing for the selection of appropriate treatments (Jaki, 2015).
Through early stopping, MAMS trials are efficient in reducing the expected number of pa-
tients required. They allow dropping treatments that are demonstrated to be ineffective/showing
lack of promise or stopping the trial altogether. Alternatively a declaration of efficacy is possi-
ble. Given the multiple hypotheses and highly adaptive nature of the design, formal inference in
MAMS studies requires specialist testing methodology in order to control the error rate of the
trial such as sequential testing methodology Stallard and Todd (2003). Magirr and others (2012)
introduced the generalised Dunnett family of tests, where well known group sequential Hatfield
and others (2016) testing boundaries are defined to account for the multiple stages introduced
by the interim analyses while accounting for the correlation introduced by the comparison of
several experimental arms to a common control Dunnett (1955); we focus our discussion around
this method. Alternatively fully flexible testing methods have been proposed Bretz and others
(2006); Schmidli and others (2006), these allow the decision making about which arms should re-
main in the study to function separately from the hypothesis testing without impacting the error
rate. Both methods require the pre-definition of all study hypotheses, so that the overall testing
procedure may be constructed to give strong control of the FamilyWise Error Rate (FWER)
(Dmitrienko and others, 2009).
To make best use of the efficiency of a MAMS design it is desirable to include all experimental
treatments for comparison with the common control; this brings further benefit of between treat-
ment comparisons being available from the same trial data. However it is possible that not all
experimental treatments are available at the start of the trial as, for example, see in the STAM-
PEDE trial Sydes and others (2009). STAMPEDE started with five comparisons and at the time
of writing has added six new research comparisons. The motivation to include further experi-
mental treatments as they become available into the trial in progress is clear. This maintains the
benefits of a reduction in logistical and administrative effort and speeding up the overall develop-
ment process Parmar and others (2008) as well as allowing direct comparisons of the treatments
within the same trial.
Treatments may be added to the trial in progress by adjusting the pre-planned testing struc-
ture provided no use has been made of the data observed in the trial (in our view this includes
knowledge that an interim analysis has happened, as this gives insight into the treatment effect
due to the pre-defined stopping boundaries). Bennett and Mander (2020) demonstrate how to
suitably adjust the sample size for each treatment arm for such additions but make no use of
any existing trial data in doing so. It is clearly possible that treatments may become available
after some interim analysis, where it would be desirable to incorporate some knowledge of trial
information into the decision making.
The conditional error approach Proschan and Hunsberger (1995) allows for design modifica-
tions during the course of a trial, where these modifications have not been pre-planned. With
work showing how these modifications may be accounted for in the setting of treatment selection
Koenig and others (2008); Magirr and others (2014) however, adding hypotheses to a testing
framework using this method requires tests of any introduced hypotheses to be constructed at
level α Hommel (2001). We propose a general framework relying on the conditional error principle
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for the inclusion of additional hypotheses to a testing procedure, allowing for the incorporation of
existing trial information where permissible. With this framework in place we show its application
in our motivating MAMS example, demonstrating how to construct an appropriate hypothesis
testing structure for the updated trial such that the FWER is strongly controlled as desired.
We give examples of this showing how the testing structure changes and how the trial may be
expected to behave going forward, comparing this to the performance of existing methods.
2. Altering a trial in progress
2.1 A two arm trial
To demonstrate the necessary principles for adding treatments to an ongoing trial let us first
consider the simpler setting of a two arm trial. Suppose we plan a trial to compare a new treat-
ment, T1, and a control, T0. Let µ1 and µ0 be the expected responses for patients on treatments
T1 and T0 respectively, and define the treatment effect as θ1 = µ1 − µ0. We investigate the one
sided null hypothesis H01 : θ1 6 0, which we test at the nominal type I error level α.
Without loss of generality the trial will recruit a total of n patients randomised equally
between treatment and control. Let Xi,k ∼ N(µk, σ2) for i = 1, ..., n/2 and k = 0, 1 then θˆ1 is
the test statistic. This has corresponding Z-value
Z1 =
θˆ1
√
n
2σ
∼ N(ξ1, 1)
where
ξ1 =
θ1
√
n
2σ
,
under the null hypothesis ξ1 = 0. We reject H01 when Z1 > Φ
−1(1−α), where Φ is the standard
normal cdf. Note that we are not restricted to any particular form of data by this choice to
describe the results in terms of Z-values as for any test statistic we may find the corresponding
Z-value.
2.2 Adding a treatment
Suppose for τ ∈ (0, 1) after τn observations a new treatment, T2, becomes available. Let µ2 be
the expected response for patients receiving this new treatment and define the corresponding
treatment effect by θ2 = µ2 − µ0. We add T2 to the trial in order to test the additional null
hypothesis H02 : θ2 6 0.
Suppose without loss of generality we do not change the pre-planned elements of the trial
concerning treatments T1 and T0, such as maintaining the same sample size per treatment arm
already present in the trial. Notationally it is convenient to split the trial into two stages, stage
1 contains the observations collected before the new treatment is added and stage 2 contains the
observations collected after the new treatment is added. Thus from the stage 1 data we find the
z-value
Z
(1)
1 ∼ N(ξ1
√
τ , 1)
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and from the stage 2 data we find the z-value
Z
(2)
1 ∼ N(ξ1
√
1− τ , 1).
The overall z-value may be reconstructed from the stagewise Z-values
Z1 =
√
τZ
(1)
1 +
√
1− τZ(2)1 .
We must recruit additional patients in order to examine the new treatment T2; say we recruit
a further (1− τ)n/2 patients maintaining equal randomisation to all treatments. Since T2 is only
added to the trial for the second stage, the comparison of T2 and T0 is made based only on the
data available from the second stage of the trial from which we construct the z-value
Z2 ∼ N(ξ2
√
1− τ , 1).
Where
ξ2 =
θ2
√
n
2σ
.
Due to the common control in the second stage of the trial and the equal randomisation Z
(2)
1 and
Z2 have correlation 1/2.
Note that the choice to recruit a further (1 − (τ)n/2 patients to each treatment arm after
the interim analysis is not a strict requirement. The methods that follow allow complete freedom
over the choice of the sample size for each treatment arm going forward. For example one might
consider optimising the sample size to each arm of the trial as was considered by Bennett and
Mander (2020), while also incorporating existing trial data into this decision.
2.3 Hypothesis testing
In the setting of a confirmatory clinical trial, testing multiple null hypotheses it is natural to
consider the impact on the error rate. For the two arm trial we constructed our hypothesis test
in order to control the type I error rate at some pre-defined level α, that is the probability of
falsely declaring a positive result for an ineffective treatment. A natural extension in the case of
multiple hypotheses is the FamilyWise Error rate (FWER), for the event R that we reject one
or more true null hypothesis the FWER is defined as Pθ(R). Again the interpretation of this
is the probability of falsely declaring a positive result for an ineffective treatment (for a given
θ = (θ1, θ2)).
Suppose, when adding this further experimental treatment to the trial we test each of the
null hypotheses as described in Section 2.1 at a nominal level α = 0.05, Figure 2.3 shows the
impact on the FWER as we vary τ . The two extremes of τ = 0 and τ = 1 represent the cases
where the trial is not altered: when τ = 0 all three treatments are present from the start of the
trial; when τ = 1 only the two arm trial is conducted (in which case the error rate returns to
the nominal type I error value of 0.05). For values in between we see that the FWER is inflated
when compared to the nominal α.
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Fig. 1. Inflation in the FWER when an additional hypothesis is added to an ongoing two arm trial.
To account for the multiplicity introduced to the trial we shall require strong control of the
FWER, a common requirement in the setting of a confirmatory clinical trial Dmitrienko and
others (2009), that is
Pθ(R) 6 α for all θ = (θ1, θ2). (2.1)
Sugitani and others (2018) propose methods that account for the introduction of the additional
hypothesis, this is achieved by testing any introduced hypothesis based strictly on the data col-
lected after their introduction at level α Hommel (2001). We build upon the approach, allowing
existing information to be incorporated wherever it is available.
To ensure strong control of the FWER we construct an overall closed testing procedure Mar-
cus and others (1976) that accounts for the adaptive nature of the trial within each test Koenig
and others (2008). This requires tests of H01, H02 and H0,12 = H01 ∩H02 : θ1 6 0 & θ2 6 0. We
may reject H01 globally when the local level α tests of H01 and H0,12 are rejected. Similarly we
may reject H02 globally when the local level α tests of H01 and H0,12 are rejected.
First let us consider the level α test of H01, no changes have been made to the recruitment
or analysis for this test, so as before we may reject H01 when Z1 > Φ
−1(1 − α) at the end of
the trial. However, it is useful to discuss how to construct this test using the conditional error
principal Proschan and Hunsberger (1995). Given the results from the first stage of the trial z
(1)
1
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we define the conditional error rate
A(z
(1)
1 ) = Pθ1=0(Reject H01|Z(1)1 = z(1)1 ).
The probability of rejecting the null hypothesis for the remainder of the trial must not exceed
A(z
(1)
1 ). We may write the test only in terms of the stage 2 observations while incorporating
the stage 1 data, that is we may reject H01 when Z
(2)
1 > Φ
−1(1 − A(z(1)1 )). Let f(z(1)1 ) be the
probability density function of the z-value based on the first stage data, then under the null
hypothesis H01 we have that ∫
z
(1)
1
f(z
(1)
1 )A(z
(1)
1 )dz
(1)
1 = α, (2.2)
which in turn guarantees control of the error rate at the pre-specified level α, that is
Pθ1=0(Reject H01) = α.
This test is equivalent to testing based on Z1, and gives the same overall properties.
As for testing H02, there is no existing information relating to this null hypothesis and thus
the test must be constructed purely based only on the stage 2 trial data used to construct Z2.
We reject the test for H02 when Z2 > Φ
−1(1− α).
These tests of H01 and H02 give type I error control for the pairwise tests, however do not
allow for overall rejection of the corresponding null hypotheses. In order to ensure strong control
of the FWER we now also require the test of the intersection hypothesis H0,12.
During the first stage of the trial there is no pre-planned test for this hypothesis, however
there is pre-existing information for H01 in the form of Z
(1)
1 . Hommel (2001) show how to use
such first stage information in the test of an intersection hypothesis, when adding some initially
excluded hypotheses after an interim analysis; we now apply this approach to a newly added
hypothesis. Consider the component hypotheses of H0,12, clearly H0,12 =⇒ H01, using this fact
we propose that the existing information Z
(1)
1 may contribute to the test of H0,12. Since H01 is
true we compute the conditional error rate A(z
(1)
1 ) as described previously, furthermore under
H01, z
(1)
1 is distributed such that equation 2.2 holds as before. Thus we may construct the test of
H0,12 at the end of the trial at level A(z
(1)
1 ) allowing for the incorporation of the stage one data
given by Z
(1)
1 .
For example consider a Dunnett test Dunnett (1955) for H0,12. Let
ZD = max(Z
(2)
1 , Z2)
and define the distribution (
X
Y
)
∼ N
((
0
0
)
,
(
1 1/2
1/2 1
))
.
We construct the Dunnett p-value,
PD = P(X > ZD ∪ Y > ZD)
and may reject H0,12 when PD < A(Z
(1)
1 ).
Adding treatment arms to trials in progress 7
2.4 Simulation study
ξ1 ξ2 P (Reject test of H01) P (Reject test of H02) P (Reject test of H0,12) FWER
0 0 0.05 0.05 0.05 0.05
δ 0 0.90 0.05 0.86 0.05
0 δ 0.05 0.66 0.36 0.05
Table 1. Probabilities of rejecting components of the closed testing procedure under proposed testing
procedure, type I errors highlighted in bold, δ = Φ−1(0.95) + Φ−1(0.9) such that we have power of 0.9
when testing H01 in the original trial.
Firstly we confirm that the desired error control is achieved for each hypothesis via simulation.
For each value of (ξ1, ξ2) and τ = 0.5 we simulate 1,000,000 realisations of Z1 and Z2 assuming
equal sample size in each treatment at each stage in R (R Core Team, 2019). Table 1 shows our
estimates of the probabilities of an error for the test of each hypothesis H01, H02 and H0,12, as
required this is α whichever combination of null hypotheses are true.
We now compare the overall trial performance for two alternative methods for testing the inter-
section hypothesis: the first being the method proposed above; and the second basing the test for
the intersection hypothesis only on evidence for H01, that is we reject H0,12 when Z1 > Φ
−1(1−α)
essentially treating the first null hypothesis as a gate keeping procedure. In the both procedures we
incorporate existing information Z
(1)
1 when testing H0,12 by the argument that H0,12 =⇒ H01.
Table 2 shows the probabilities of global rejection of the null hypotheses under several combina-
tions of ξ1 and ξ2 for each testing method. We confirm that the overall testing procedure gives
strong control of the FWER under all configurations of null hypotheses. The probabilities of
rejecting false H01 does not differ largely between the two testing methods, with an increase of at
most at most 0.04 for the gate keeping procedure. When both null hypotheses are false the is a
small decrease of 0.03 in the probability of rejecting H02 for the gate keeping procedure. The main
difference between the two procedures is when H01 is true and H02 is false under this configuration
it is not possible to reject H02 without making an error in rejecting H01 (indeed the probability
of rejecting a false H02 is 0.04 when H01 is true) and thus our proposed procedure increases the
probability of rejecting the H02 by 0.29. It is clear that the small advantage for testing H01 for the
gate keeping procedure is outweighed by the ability to reject H02 when there is a low probabil-
ity of rejecting H01 when taking an integrated approach to the test of the intersection hypothesis.
In order to understand the performance of the proposed testing procedure we examine the
probabilities of rejecting the intersection hypothesis H0,12 under the 4 proposed scenarios in
Figure 2 (all combinations of H01 and H02 true and false). We see that when H01 is false the
conditional error is likely to be higher than the pre-planned α, usually giving a high chance of
rejecting H0,12; although when H01 is true and H02 is false there is a small reduction in the
probability of rejecting H0,12, this explains the small deficit of the proposed procedure compared
to testing based only on H01 when ξ1 = δ and ξ2 = 0. Conversely when H01 is true we see that the
conditional error is likely to be quite low: when both null hypotheses are true this corresponds
to a low probability of rejecting H0,12 as is to be expected; however when H02 is false as the
conditional error rate rises we recover some possibility of rejecting the intersection hypothesis
allowing us to reject H02 globally.
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Dunnett procedure for testing the intersection hypothesis
ξ1 ξ2 P (Reject H01 only) P (Reject H02 only) P (Reject both) P (Reject any)
0 0 0.03 0.01 0.01 0.05
δ 0 0.81 0.00 0.05 0.86
0 δ 0.00 0.29 0.04 0.33
δ δ 0.26 0.03 0.62 0.91
Gate keeping procedure for testing the intersection hypothesis
ξ1 ξ2 P (Reject H01 only) P (Reject H02 only) P (Reject both) P (Reject any)
0 0 0.04 NA 0.01 0.05
δ 0 0.85 NA 0.05 0.90
0 δ 0.01 NA 0.04 0.05
δ δ 0.28 NA 0.62 0.90
Table 2. Probabilities of global rejection of null hypothesis using the conditional error approach, type I
errors highlighted in bold, δ = Φ−1(0.95) + Φ−1(0.9) such that we have power of 0.9 when testing H01 in
the original trial.
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Fig. 2. Conditional error rate, A(z1(1)), against probability of rejecting the intersection hypothesis
P (Reject H0,12|z(1)1 ) and corresponding density of conditional error f(z(1)1 , δ = Φ−1(0.95) + Φ−1(0.9)
such that we have power of 0.9 when testing H01 in the original trial.
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3. General rule for hypothesis adding
Suppose there is a set of existing null hypotheses E with an existing pre-planned closed testing
procedure, to which we wish to add a set of new null hypotheses N . Let He be the intersection
of some subset of the existing null hypotheses e ⊆ E and Hn be the intersection of some subset
of the new hypotheses n ⊆ N . To construct the updated closed testing procedure for the end of
the trial there are three scenarios to consider, we are either testing hypotheses of the form He,
Hn or He ∩Hn.
He: Let α
′
e be the conditional error rate for the test of He at the time the N hypotheses
are added, we construct the test of He such that the probability of falsely rejecting He does not
exceed α′e.
Hn: There is no pre-existing information concerning the test of this hypothesis and thus it
must be tested at level α.
He∩Hn: as noted in the three arm case He∩Hn =⇒ He and hence the data already available
for He is distributed such that computing the corresponding conditional error α
′
e will ensure that
an equation of the form 2.2 holds. Thus we may incorporate the existing information on He into
the test by constructing the test for He∩Hn such that the probability of falsely rejecting He∩Hn
does not exceed α′e.
It is crucial that the test of any intersection of the form He ∩Hn is constructed in this way.
Consider that while proposing changes to the trial one may or may not choose to add any new
hypotheses Hn: in the case where Hn added then He ∩ Hn may be based on the data relating
to both He and Hn and is tested at α
′
e; while if Hn is not added then implicitly the test for
He ∩ Hn is implicitly that of He also tested at α′e. In either case the test of He ∩ Hn is based
on the error level α′e ensuring that an equation of the form 2.2 holds whatever decision is made
while proposing changes to the trial design.
Noting further that any procedure that gives strong control of the FWER is indeed a closed
testing procedure Burnett (2017). This method allows any procedure that ensures strong control
of the FWER to include additional hypotheses that were not included at the design stage while
maintaining the statistical integrity of the trial. The penalty for doing so compared to separate
trials is the test of hypotheses of the form He ∩Hn and is the potential efficiency of these tests
that will dictate whether it is a sensible approach or not. However if the treatments co-exist in
the research environment there is clear motivation for including them in the same trial as is the
case in Multi-Arm Multi-Stage designs.
4. Alteration of a Multi-Arm Multi Stage trial in progress
4.1 Introduction to a Multi-Arm Multi-Stage setting
Take the case of two experimental treatments and a common control from Section 2.1. Had we
known that this additional comparison would have been of interest at the start of the trial we
should instead considered a Multi-Arm Multi-Stage design Jaki (2015); Wason and others (2016).
This would maintain the ability to compare multiple experimental treatments with a common
control, while incorporating one or more interim analyses to allow for early stopping.
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The use of one or more pre-planned interim analyses ensures: poorly performing treatments
may be dropped for futility, protecting patients on the trial from an inferior treatment; alterna-
tively the trial may be stopped early to declare efficacy, reducing the overall development time
and number of patients. These early stopping characteristics may be achieved while formally test-
ing null hypotheses for each treatment for example through the use of generalised Dunnett type
testing procedures Magirr and others (2012) or fully flexible methods Bretz and others (2006);
Schmidli and others (2006). We shall focus on generalised Dunnett type methods here although,
as noted in Section 3, the methods apply to any procedure that gives strong control of the FWER.
4.2 Multi-arm multi-stage trials
Suppose at the outset of the trial we have K novel treatments, T1, ..., TK that we wish to com-
pare against a common control. We define the null hypotheses H0i : θi 6 0 and corresponding
alternatives H1i : θi > 0 for all i = 1, ...,K. We shall now consider a J stage MAMS trial will
allow us to simultaneously test these initial K null hypotheses.
Let n be the number of patients to be recruited to the control arm in the first stage of the
trial. Assuming that the recruitment and randomisation procedures for the trial are such that
we can achieve the desired number of patients on any given arm at any given time. At stage
j = 1, ..., J we have recruited rk,jn patients to treatment k = 0, 1, ...,K. Treatments may be
dropped futility at the end of each stage of the trial, suppose treatment k∗ is stopped at analysis
j∗ we have rk∗,j = rk∗,j∗ for all j > j∗. Alternatively the entire trial may stop recruiting early if
a treatment or treatments have been selected for further study, such as when the trial is stopped
due to a treatment-control comparison yielding statistical significance Urach and Posch (2016).
From the observations at each stage j = 1, ..., J and treatment k = 1, ...,K we construct
estimates θˆk,j . Defining
Ik,j = rk,jr0,jn
σ2(rk,j + r0,j)
,
we find the corresponding Z-values
Zk,j = θˆk,jI1/2k,j .
As was the case for the two arm trial described in Section 2.1 the choice to define the trial in
terms of the Z-values is not restrictive, for other choices of test statistic we may simply find the
corresponding Z-values.
4.3 The Generalised Dunnett procedure
Recall that R is the event that we reject one or more true null hypothesis then extending Equa-
tion 2.1 to a general K null hypothesis strong control requires that
Pθ(R) 6 α for all θ = (θ1, ..., θK). (4.3)
The generalised Dunnett method introduced by Magirr and others (2012) allows the simultaneous
testing of null hypotheses in a MAMS design, defining group sequential testing boundaries that
account for the correlation structure of comparing multiple treatments to control to achieve the
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desired FWER.
For each stage of the trial we define efficacy boundaries u = (u1, ..., uJ) where the null hy-
pothesis in treatment group k = 1, ...,K, H0k, is rejected at stage j of the trial if Zk,j > uj ;
after any null hypothesis has been rejected the trial is concluded, accumulating no more data. In
addition we define futility stopping boundaries l = (l1, ..., lJ) where if Zk,j < lj the corresponding
treatment is dropped for futility, meaning that patients are no longer recruited to this treatment.
To achieve strong control of the FWER Magirr and others (2012) show it is sufficient to
set the stopping boundaries such that the probability of rejecting any null hypothesis under the
global null, θ1 = ... = θK = 0 which we denote by 0, does not exceed the nominal error rate α.
Noting that under the generalised Dunnett procedure the FWER is maximised under the global
null, thus we must choose u and l such that
P0(R) 6 α. (4.4)
Magirr and others (2012) showed how to compute such testing boundaries uj and lj for
j = 1, ..., J while applying familiar group sequential theory testing. The MAMS package in R Jaki
and others (2019) allows for the construction of tests following predefined shapes including Pocock
(1977) Pocock (1977), O’Brien & Fleming (1979) O’Brien and Fleming (1979) and triangular
Whitehead (1997) type testing boundaries.
4.4 Adding experimental treatment arms
With this setting in mind suppose that a trial is still in progress after stage J ′ ∈ (1, ..., J). At
this interim analysis outside of the trial T > 1 new treatments become available. Adding these
to our trial in progress allows us to assess whether they offer an improvement over those already
being assessed, without delaying the overall development process or the need to start a trial for
the new treatments.
We now have up to K ′ = K+1+T treatments for the trial in total (in the case that all K+1
original treatment arms are all still in the trial). For the existing K + 1 treatments we shall not
alter the recruitment, maintaining that described in Section 4.2. For the new treatments there is
clearly no recruitment before they are added and hence rk,j = 0 for k = K + 1, ...,K + T and
j = 1, ..., J ′ and thus there are no corresponding Z-values. In order to add these new treatments
we add recruitment rk,jn for each new treatment k = K + 1, ...,K + T over the remaining trial
stages j = J ′ + 1, ..., J ; note that this recruitment is planned and fixed at the point where the
new treatments are added.
As usual we construct estimates for each additional treatment at each stage of the trial they
are present for. For treatment k = 1, ...,K + T at stage j = J ′ + 1, ..., J the Z-value is given by
Zk,j = θˆk,jI1/2k,j .
4.5 Incorporating additional hypotheses
To make formal inference about the additional treatments we incorporate formal testing of addi-
tional hypotheses. Incorporating the new hypotheses we now have the null hypotheses H0i : θi 6 0
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and alternatives H1i : θi > 0 for all i = 1, ...,K + T , and require strong control of the FWER
across all K + T tests.
For the treatments originally included in the trial we wish to incorporate the information
from the existing estimates up the the current stage of the trial, θˆJ′ = (θˆJ′,1, ..., θˆk,J ′). We
extend Equation 2.1 to write the FWER conditional on the observations from the trial so far
Pθ(R|θˆJ′) 6 α for all θ = (θ1, ..., θK). (4.5)
As in Section 2.2 we make use of the independent increments of the Z-values in order to split
the trial according to data gathered in the first J ′ stages and gathered after. For j = J ′+ 1, ..., J
and k = 0, 1, ...,K the sample that may be recruited after stage J ′ is governed by r′k,j = rk,j−rk,J ′ ,
from which we compute corresponding Z-values Z ′k,j . For each of the treatment arms from the
first stage of the trial k = 1, ...,K we define weights for data before and after stage J ′, for
j = J ′ + 1, ..., J and k = 1, ...,K
w1,k,j =
√
rk,J ′ + r0,J′
rk,j + r0,j
,
w2,k,j =
√
1− w21,k,j
and re-construct the Z-values for the remainder of the trial as
Zk,j = w1,k,jZk,J′ + w2,k,jZ
′
k,j .
It is also useful to re-write the rejection boundaries in terms of only the data collected after stage
J ′, that is for j = J ′ + 1, ..., J and k = 1, ...,K
u′k,j =
uj − w1,k,jZk,J′
w2,k,j
where the null hypothesis for treatment k = 1, ...,K, H0k, is rejected at stage j of the trial if
Z ′k,j > u
′
k,j and
l′k,j =
lj − w1,k,jZk,J ′
w2,k,j
where if Z ′k,j < l
′
k,j the corresponding treatment is dropped for futility.
Under a generalised Dunnett procedure the conditional FWER is maximised under the global
null Stallard and others (2015), see the supplementary material 7.1 for details. Given this we
write the conditional error under the global null as
B0(θˆJ′) = P0(R|θˆJ′) 6 α.
As in Equation 2.2 we have that under the global null∫
θˆJ′
f(θˆJ′)B0(θˆJ′)dθˆJ′ = α, (4.6)
and thus ensuring the conditional FWER is not exceeded for the remainder of the trial for the
K initial null hypotheses ensures strong control of the FWER with respect to these endpoints.
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To construct our overall testing procedure let us think in terms of existing null hypotheses of
the form H0e for which the error rate must not exceed B0(θˆ
J′) and new null hypotheses H0n for
which the error rate must not exceed α as in Section 3. We construct testing boundaries as for the
generalised Dunnett, accounting for the conditioning where possible to allow the incorporation of
all trial data. As seen in Section 4.3 when we talk about constructing boundaries in this Section
this may be done following one of several pre-defined shapes; when constructing boundaries in
the Section we further assume that shape of boundary is always of the same type.
For existing treatments k = 1, ...,K we define the updated testing boundaries for j = J ′ +
1, ..., J as u′j and l
′
j , again it is a useful computational trick to write the boundaries incorporating
the conditional information using independent increments for k = 1, ...,K
u′k,j =
u′j − w1,k,jZk,J′
w2,k,j
where the null hypothesis in treatment group k = 1, ...,K, H0k, is rejected at stage j of the trial
if Zk,j > u
′
k,j and
l′k,j =
l′j − w1,k,jZk,J ′
w2,k,j
where if Zk,j < lk,j the corresponding treatment is dropped for futility. For the T added treat-
ments we have for j = J ′+1, ..., J as u∗j and l
∗
j , where for treatment k = K+1, ...,K+T at stage
j = J ′+1, ..., J we stop the trial and reject H0k if Zk,j > u∗j and we drop the treatment for futility
if Zk,j < l
∗
j . To ensure that both the existing endpoints and the additional endpoints are tested
at the appropriate error rate we consider two cases when constructing the testing boundaries.
When α < B0(θˆ
J′) first construct the testing boundaries for the T added treatments, then
with these fixed we set the boundaries for the original K novel treatments (or what remains of
the after the interim analysis). We set the testing boundaries for the introduced endpoints u∗j and
l∗j at level α using the usual MAMS framework for a trial with J − J ′ stages and T experimental
treatments. Given u∗j and l
∗
j we then find values for u
′
j and l
′
j such that the continuing MAMS
trial with J − J ′ stages and K + T treatments is constructed such that the error rate for the
FWER under the global null does not exceed B0(θˆ
J′) conditional on the data from the first J ′
stages of the trial. Note that constructing u′j and l
′
j in this way is in the worst case (in terms of
the FWER) equivalent to constructing a MAMS trial with J − J ′ stages and K + 1 treatments
(if all K experimental treatments are still present) with an error rate of B0(θˆ
J′) under the same
shape of testing boundaries (see the supplementary material 7.2 for full details). This fulfils the
conditions introduced in Section 3 for constructing the overall closed testing procedure as all
implied tests for hypotheses involving H0e are at level α by construction of B0(θˆ
J′) while all
implied tests for introduced hypotheses H0n are at level α.
Alternatively when α > B0(θˆJ
′
) we will have equal testing boundaries for all treatments,
u∗j = u
′
j and l
∗
j = l
′
j . In this case we choose the u
∗
j , u
′
j , l
∗
j and l
′
j such that the continuing MAMS
trial with J − J ′ stages and K + T treatments has a FWER under the global null of B0(θˆJ′)
conditional on the data from the first J ′ stages of the trial. We note that the tests of H0n are
conservative in this case, in particular the implied tests of introduced hypotheses H0n are at level
B0(θˆ
J′). Since any particular H0n may only be rejected globally based on B0(θˆ
J′) this is not a
concern.
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5. Example
5.1 An illustrative example
We now explore the performance of our proposed method. We begin by exploring how the modifi-
cation of the trial may be conducted. For the initially planned MAMS trial consider a three stage
trial to compare two novel treatments with a common control, recruiting an equal number of pa-
tients to each treatment across each stage of the trial; that is J = 3, K = 2 and rk = (1, 2, 3) for
k = 0, 1, 2. Under this design we formally test the null hypotheses H01 : θ1 6 0 and H02 : θ2 6 0.
The testing boundaries are constructed such that the FWER is strongly controlled at α = 0.05,
let δ = Φ−1(0.75)
√
2 and σ = 1 (note this choice of δ and σ corresponds to a probability of 0.75
that a randomly selected person on the experimental treatment performs better than a randomly
selected person on the control) then at a configuration of θ = (δ, 0) we have a target power of
1− β = 0.9. Defining the triangular type testing boundaries Whitehead (1997) the details of the
pre-planned MAMS trial computed using the mams() function of the MAMS package in R Jaki
and others (2019). In this design we recruit 10 patients per treatment arm per stage, given a
maximum possible sample size of 90 patients. For stopping the trial we have upper boundaries
u = (2.435, 2.152, 2.109) and lower boundaries l = (0.000, 1.291, 2.109) (this lower boundary is
treat as a binding futility boundary although non-binding futility boundaries are also possible).
Suppose after the first analysis J ′ = 1 we wish to add two novel treatments to the trial T = 2,
adding the null hypotheses H03 : θ3 6 0 and H04 : θ4 6 0. Let the observations from the first
stage of the trial be Z1 = (2, 1.5), for which the trial would continued in all arms at the interim
analysis, this gives B0(θˆ1) = 0.24 from which we may plan the rest of the trial. In this case we
have B0(θˆ1) > α and thus when constructing the stopping boundaries for the remainder of the
trial we have different stopping boundaries for the introduced arms and those already in the trial.
For the introduced arms we compute upper boundaries for stages 2 and 3 u∗ = (2.179, 2.055) and
lower boundaries l∗ = (0.726, 2.055); then for the existing arms we compute upper boundaries
u′ = (2.240, 2.111) and lower boundaries l′ = (0.747, 2.111). Maintaining equal randomisation to
all arms we recruit 10 patients per treatment per stage, allowing for a maximum total sample size
of 130 patients (including the 30 already recruited). Note that the boundaries for rejecting the
pre-planned treatments have shifted slightly compared with the original trial due to the incorpo-
ration of the additional hypotheses. In this particular case the added hypotheses have a stricter
set of testing boundaries than those in the pre-planned trial protocol.
Using this design we simulate the remainder of the trial under different configurations of θ.
Table 3 shows the operating characteristics of the updated trial based on 1000 simulations. We
see that as expected for each hypothesis the probability of rejecting the null hypotheses does
not exceed B0(θˆ1) = 0.24 or α = 0.05 when the the corresponding θi = 0 as required by the
construction of our test; indeed in most cases we are somewhat conservative for each individual
hypothesis globally, but recall for the FWER we are concerned with rejecting one or more null
hypotheses and so this conservatism is necessary. Examining the probabilities of rejecting multi-
ple hypotheses we confirm that under the global null we have achieved a conditional FWER of
B0(θˆ1) = 0.24 as expected.
From Table 3 we may also asses the performance where the null hypothesis is false. We see a
higher probability of rejecting H01 and H02 (due to the relatively positive results from the first
stage of the trial), with high probabilities of rejecting H01 (the better treatment according to the
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θ Pθ(R1) Pθ(R2) Pθ(R3) Pθ(R4) Eθ(N)
(0, 0, 0, 0) 0.17 0.08 0.03 0.02 72 (+30)
(δ, 0, 0, 0) 0.97 0.05 0.01 0.01 54 (+30)
(0, δ, 0, 0) 0.13 0.93 0.02 0.02 59 (+30)
(0, 0, δ, 0) 0.13 0.06 0.79 0.02 65 (+30)
(δ, δ, 0, 0) 0.92 0.76 0.01 0.01 53 (+30)
(0, 0, δ, δ) 0.14 0.05 0.68 0.70 62 (+30)
(δ, δ, δ, δ) 0.90 0.74 0.52 0.52 53 (+30)
θ Fail to reject Reject one Reject two Reject three Reject four
(0, 0, 0, 0) 0.76 0.20 0.04 0.01 0.00
(δ, 0, 0, 0) 0.02 0.91 0.06 0.01 0.00
(0, δ, 0, 0) 0.06 0.80 0.12 0.01 0.00
(0, 0, δ, 0) 0.18 0.67 0.12 0.02 0.00
(δ, δ, 0, 0) 0.01 0.30 0.67 0.02 0.00
(0, 0, δ, δ) 0.07 0.43 0.39 0.10 0.02
(δ, δ, δ, δ) 0.00 0.18 0.25 0.29 0.29
Table 3. Operating characteristics for the remainder of the trial given Z1 = (2, 1.5) under corresponding
configuration θ. Where Ri is the event that H0i is rejected and N is the total sample size (note 30
participants already recruited).
interim analysis). For the added experimental treatments we have a reasonable chance to reject
the null hypotheses, particularly when there is no benefit to the original experimental treatments,
although it would appear that it takes slightly longer to find this result.
5.2 Comparison of performance
Suppose again at the first interim analysis J ′ = 1 we wish to add two further treatment arms
T = 2 to a trial in progress. Our proposed method is not the only way one might study the
additional treatment arms. Considering an integrated approach (as suggest by our example in
Section 2.4). We shall compare with two options that maintain the integrity of the results given
that observations are already available from the trial: option 1 is to conduct another separate
MAMS trial comparing the new treatments with the control (not this means that patients must
be recruited to the control in both trials); option 2 is to conclude the current trial at the interim
analysis and start a new trial incorporating all four experimental treatments. If the original trial
concludes statistical significance at the interim analysis we assume no treatment is studied further
under all three scenarios.
We perform simulations, generating 1000 realisations of the trial (including the first stage), to
evaluate the overall operating characteristics of the trials continuing under each of these options.
Table 5.2 shows the probability of the trial continuing beyond the first interim analysis under
each of our configurations of interest, we see that: under the global null the probability that the
trial continues beyond the first interim analysis is 0.65 (applying binding futility boundaries); if
θ1 or θ2 = δ we have a high probability of the trial stopping early to declare efficacy of 0.39 with
a probability of 0.6 of the trial continuing beyond the first interim analysis; if the treatment effect
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is present in both the experimental treatments there is a probability of 0.54 of stopping the trial
early to declare efficacy.
θ Pθ(Stop early for futility) Pθ(Stop early for efficacy)
(0, 0) 0.33 0.02
(δ, 0) 0.01 0.39
(δ, δ) 0.00 0.54
Table 4. Characteristics of trial adding endpoints conditional on stage 1.
Let us examine the overall operating characteristics, where if the trial continues beyond the
interim analysis we follow either our proposed method or one of the other 2 options to add the
arms. Table 5 shows under our proposed method: as expected under the global null the FWER
is strongly controlled; when only H01 is false there is a probability of 0.92 of rejecting it, falling
to a probability of 0.72 of rejecting H01 when H02 is also false due to the possibility to conclude
the trial early for efficacy elsewhere; when only H03 is false the probability of rejection is 0.48,
this falls to 0.40 when H01 is false due to the probability of stopping the trial early due to an
arm with more data, and when H04 is also false there is a probability of rejecting each false
hypothesis of 0.42; if all experimental arms offer a benefit over the control we see a probability
of 0.69 of rejecting H01 and H02 and 0.23 of rejecting H03 and H04. The probability to reject
one or more null hypotheses with our proposed method varies largely depending on which treat-
ments are effective: when either H01 or H02 are false there is a high probability of rejecting 1 or
more null hypotheses, greater than 0.9 in all configurations investigated; whereas if H03 or H04 are
false there is around a 0.5 chance of rejecting one or more null hypotheses if H01 and H02 are true.
We compare our proposed method with the characteristics of conducting a separate trial for
the new arms in Table 6. The probabilities of rejecting H01 and H02 are slightly higher, however
while each trial protects the FWER within the trial there is no overall adjustment to the error
rate across the two trials. This improvement is only 0.01 when only H01 and/or H02 are false, with
larger increases when one or more of H03 and H04 are false; however the probability of rejecting
one or more null hypotheses are consistent between methods, not differing by more than 0.02 un-
der the configurations investigated. There are larger increases in the probability of rejecting H03
and H04, this is due to the fact if the trial has continued beyond the first interim analysis under
our proposed method the trial as a whole may conclude early due to demonstrated efficacy in the
first two treatments. Our proposed method gives a probability of 0.94 of rejecting one or more
treatments from the same trial when there is an effect in one of the original treatments and one
of the added, while the original trial matches this probability it is not possible to simultaneously
make the comparison with the other experimental treatment. The number of patients required
by the two separate trials increases by around 20 patients under the configurations investigated.
When we start a new trial to incorporate all the treatments we see from Table 7 the prob-
ability of H01 or H02 when they are false is reduced by around 0.05 (varying slightly based on
exact configuration). This difference is entirely driven by the second and third stages of the trial.
The probabilities of rejecting false H03 or H04 differ by only 0.01 at most. The more noticeable
difference is a consistent trend of higher probabilities of rejecting multiple null hypotheses under
our proposed method. In addition when restarting the trial the sample size is increased by around
15 patients across all configurations we investigate.
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θ Pθ(R1) Pθ(R2) Pθ(R3) Pθ(R4) Eθ(N) (excluding first stage)
(0, 0, 0, 0) 0.02 0.02 0.01 0.01 56
(δ, 0, 0, 0) 0.92 0.01 0.01 0.01 52
(0, 0, δ, 0) 0.02 0.02 0.48 0.01 59
(δ, 0, δ, 0) 0.85 0.01 0.40 0.01 52
(δ, δ, 0, 0) 0.72 0.72 0.01 0.01 47
(0, 0, δ, δ) 0.01 0.01 0.42 0.42 60
(δ, δ, δ, δ) 0.69 0.69 0.23 0.23 44
θ Fail to reject Reject one Reject two Reject three Reject four
(0, 0, 0, 0) 0.95 0.04 0.01 0.00 0.00
(δ, 0, 0, 0) 0.08 0.89 0.03 0.01 0.00
(0, 0, δ, 0) 0.51 0.47 0.02 0.00 0.00
(δ, 0, δ, 0) 0.06 0.62 0.32 0.01 0.00
(δ, δ, 0, 0) 0.03 0.49 0.47 0.01 0.00
(0, 0, δ, δ) 0.42 0.32 0.25 0.01 0.00
(δ, δ, δ, δ) 0.01 0.43 0.35 0.09 0.11
Table 5. Under our proposed update procedure, probabilities of rejecting null hypotheses and expected
sample size under the corresponding configuration of θ for our proposed update procedure. Where Ri is
the event that we reject Hoi and N is the total sample size.
θ Pθ(R1) Pθ(R2) Eθ(N1) Pθ(R3) Pθ(R4) Eθ(N2)
(0, 0, 0, 0) 0.03 0.03 49 0.02 0.02 25
(δ, 0, δ, 0) 0.93 0.01 47 0.50 0.01 24
(δ, δ, δ, δ) 0.73 0.73 46 0.32 0.32 18
Original trial Additional trial
θ Fail to reject Reject one Reject two Fail to reject Reject one Reject two
(0, 0, 0, 0) 0.95 0.05 0.00 0.97 0.03 0.00
(δ, 0, δ, 0) 0.07 0.92 0.01 0.50 0.49 0.01
(δ, δ, δ, δ) 0.01 0.51 0.48 0.57 0.21 0.21
Table 6. Under two separate trials, probabilities of rejecting null hypotheses and expected sample size
under the corresponding configuration of θ for our option 1 assuming the trial continues beyond the
interim analysis. Where Ri is the event that we reject Hoi, N1 is the total sample size in the original
trial and N2 is the total sample size in the additional trial.
6. Discussion
The motivation for adding a treatment to a trial in progress is clear. Should a new treatment be-
come available it is desirable incorporate it allowing direct comparisons while preserving integrity
and avoiding delays to the overall development process. Furthermore there are many practical
benefits. For example, when adding treatments to the trial in progress, while requiring a change
to randomisation procedures and an increase in the total possible recruitment, the adaptive na-
ture of the design trial will mean centres are well prepared for such changes.
Our proposed general framework for adding experimental treatments to a trial in progress
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θ Pp(R1) Pp(R2) Pp(R3) Pp(R4) Ep(N) (excluding first stage)
(0, 0, 0, 0) 0.02 0.02 0.01 0.01 71
(δ, 0, 0, 0) 0.84 0.02 0.01 0.01 68
(0, 0, δ, 0) 0.01 0.01 0.49 0.01 71
(δ, 0, δ, 0) 0.78 0.01 0.39 0.01 67
(δ, δ, 0, 0) 0.67 0.67 0.00 0.00 59
(0, 0, δ, δ) 0.01 0.01 0.41 0.41 70
(δ, δ, δ, δ) 0.63 0.63 0.25 0.25 59
θ Fail to reject Reject one Reject two Reject three Reject four
(0, 0, 0, 0) 0.95 0.04 0.00 0.00 0.00
(δ, 0, 0, 0) 0.16 0.82 0.02 0.00 0.00
(0, 0, δ, 0) 0.49 0.49 0.02 0.00 0.00
(δ, 0, δ, 0) 0.08 0.67 0.24 0.01 0.00
(δ, δ, 0, 0) 0.05 0.54 0.40 0.01 0.00
(0, 0, δ, δ) 0.41 0.33 0.25 0.01 0.00
(δ, δ, δ, δ) 0.02 0.46 0.34 0.10 0.08
Table 7. Under starting a new trial incorporating all treatments, probabilities of rejecting null hypotheses
and expected sample size under the corresponding configuration of θ for option 2 assuming the trial
continues beyond the interim analysis. Where Ri is the event that we reject Hoi and N is the total
sample size.
builds upon the work of Hommel (2001), allowing any trial with strong control of the FWER
to add new hypotheses. This is achieved while simultaneously allowing other alterations to the
design of the trial using the conditional error principal. The additional benefit of this approach
is that we ensure that all information already collected from volunteers to our trial is utilised in
inference and decision making. When comparing our proposed approach to possible alternatives
we see from the results in Section 2.4 that our introduced approach is preferable.
This framework can be applied in our motivational setting of MAMS platform trials. The ex-
amples in Section 5 demonstrate that this does indeed strongly control the FWER as expected.
The penalty of doing so in terms of the probability of rejecting the null hypotheses is marginal
and only has a notable impact on the introduced arms, optimising the recruitment proportions
across configurations of the true treatment effects may reduce the impact of this further. In addi-
tion the combination of utilising the existing data and the efficient use of control patients across
the trial yields a reduction in the expected sample size when compared to alternatives that do
not make such use of the existing data.
The improvement of operating characteristics is not the primary motivation to adding treat-
ments to a trial in progress. As is the argument for MAMS trials in general this allows for
reduction in logistical and administrative effort and speeding up the overall development process
as well as allowing direct comparisons of the treatments within the same trial.
Our general method for adding hypotheses to a trial in progress has broader application than
the MAMS trials within which we have applied it. As noted in Section 3 any testing procedure
that gives strong control of the FWER may be written as a closed testing procedure and thus
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this methodology may be used to add hypotheses to any trial in progress where strong control
of the FWER is required. The addition of hypotheses in this way allows for the incorporation of
existing trial data into decisions about how to plan the remainder of the trial; though the decision
over which hypotheses should be test should not be data dependent.
7. Supplementary material
7.1 Conditional FWER
To see that the conditional FWER is maximised under the global null we consider the crucial
element of the proof provided by Magirr and others (2012). The claim is that for
Ak,j(δk) =
{
Zk,j < lj + (µk − µ0 − δk)I1/2k,j
}
(7.7)
and
Bk,j(δk) =
{
lj + (µk − µ0 − δk)I1/2k,j < Zk,j < uj + (µk − µ0 − δk)I1/2k,j
}
(7.8)
and any  > 0 we have that
J⋃
j=1

j−1⋂
j=1
Bi,k(δk + k)
 ∩Ak,j(δk + k)
 ⊆ J⋃
j=1

j−1⋂
j=1
Bi,k(δk)
 ∩Ak,j(δk)
 .
Take
ω = (Z1,k, ..., Zk,j) ∈
J⋃
j=1

j−1⋂
j=1
Bi,k(δk + k)
 ∩Ak,j(δk + k)
 .
For some m ∈ (1, ..., J , Zk,m ∈ Ak,j(δk + k) and Zk,m ∈ Bk,j(δk + k) for j = 1, ...,m − 1.
We have that Zk,m ∈ Ak,j(δk + k) implies Zk,m ∈ Ak,j(δk) and Zk,m ∈ Bk,j(δk + k) implies
Zk,m ∈ Bk,j(δk) ∪Ak,j(δk) for j = 1, ...,m− 1. Therefore,
ω ∈
J⋃
j=1

j−1⋂
j=1
Bi,k(δk)
 ∩Ak,j(δk)
 .
Writing Equations 7.7 and 7.8 in terms of the conditional boundaries we have
Ak,j(δk) =
{
Z ′k,j < lk, j
′ + (µk − µ0 − δk)I1/2k,j
}
and
Bk,j(δk) =
{
l′k,j + (µk − µ0 − δk)I1/2k,j < Z ′k,j < u′k,j + (µk − µ0 − δk)I1/2k,j
}
,
this does not change the arguments presented above and thus this crucial condition holds.
7.2 Preserving consonance
Consider a MAMS trial for K novel treatments and a common control conducted over J stages.
Consider the efficacy boundaries u = (u1, ..., uJ) defined to achieve a FWER of α, where at in-
terim analysis j = 1, ..., J we reject H0k if Zk,j > uj for k = 1, ...,K. Equivalently we may define
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efficacy boundaries for each treatment arm uk,j , where usually u1,j = ... = uK,j for all j = 1, ..., J .
Suppose without loss of generality that for H01 we require a test at some α
′ < α, under
the same shape of testing boundary this will require a new efficacy boundary u′1,j > u1,j for all
j = 1, ..., J . In order to achieve overall α for the testing boundary we choose u′k,j 6 uk,j for all
k = 2, ...,K, j = 1, ..., J . In order to use this new efficacy boundary for global rejections of the
null hypotheses we require that the testing procedure is consonant (all implied sub-hypotheses
are tested at the appropriate level: H01 at α
′ and H02 to H0K at α) as this implied consonance
is key in why a MAMS trial is a valid closed testing procedure.
As α′ → 0 we have u′1,j →∞, assuming we always apply the same shape of testing boundary
u′k,j decreases monotonically for all k = 2, ...,K, j = 1, ..., J to ensure the overall procedure
achieves α. The limit of this decrease is, by construction, a set of testing boundaries of the
specified form for K − 1 novel treatments and a common control conducted over J stages. That
is to say as required the procedure is consonant.
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